BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30687989)

  • 1. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
    Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
    HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment.
    Sirinawasatien A; Supawan P
    Medicine (Baltimore); 2024 May; 103(19):e38096. PubMed ID: 38728473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.
    Mandorfer M; Schwabl P; Steiner S; Scheiner B; Chromy D; Bucsics T; Stättermayer AF; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    AIDS; 2016 Apr; 30(7):1039-47. PubMed ID: 26760453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
    Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
    Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
    J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
    AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    Shili-Masmoudi S; Sogni P; de Ledinghen V; Esterle L; Valantin MA; Poizot-Martin I; Simon A; Rosenthal E; Lacombe K; Pialoux G; Bouchaud O; Gervais-Hasenknoff A; Goujard C; Piroth L; Zucman D; Dominguez S; Raffi F; Alric L; Bani-Sadr F; Lascoux-Combe C; Garipuy D; Miailhes P; Vittecoq D; Duvivier C; Aumaître H; Neau D; Morlat P; Dabis F; Salmon D; Wittkop L;
    PLoS One; 2019; 14(1):e0211286. PubMed ID: 30682180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
    Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
    J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.